Skip to main content

JHOP - August 2023 Vol 13, No 4

Original Research
Practical Issues in Pharmacy Management
Review Article
FDA Updates
Original Research
Original Research, Adverse Events, VEGF Inhibitors
Effects of Vascular Endothelial Growth Factor Inhibitor–Induced Proteinuria on Treatment Course and Outcomes: Retrospective Analysis and Review of the Literature
Joshua L. Murdock, PharmD; Marissa R. Duco, PharmD; David J. Reeves, PharmD, BCOP
Read More
Original Research, Leukemia, Transplant, Antibiotics
Effects of Levofloxacin Prophylaxis in Pediatric Patients With Acute Myeloid Leukemia, Relapsed Acute Lymphoblastic Leukemia, or Patients Undergoing Hematopoietic Stem Cell Transplant
Livia Linden, PharmD, BCPPS; Sarah Timaeus, PharmD, BCOP; Jessica Gillon, PharmD, BCIDP; Savannah Gulley, PharmD, BCPPS
Read More
Original Research, PARP Inhibitors, Ovarian Cancer, Screening
Duration of Response to PARP Inhibitors for Maintenance Treatment of Ovarian Cancer in Patients With Germline or Somatic HRD
Jordanne Adolphsen, PharmD, BCOP; Taylor Monson, PharmD, BCOP; Grace Martin, PharmD, BCOP; Zahra Mahmoudjafari, PharmD, BCOP; Richard Meier, PhD; Whitney Shae, BS, MS; Devin C. Koestler, PhD; Colleen Bohnenkamp, PharmD, BCOP
Read More
Practical Issues in Pharmacy Management
Practical Issues in Pharmacy Management, Chemotherapy, Technology, Oncology Pharmacy Programs/Protocols, Oral Therapy
Impact of Pharmacist-Led Oral Chemotherapy Telehealth Clinic at a Community Cancer Center Using the TAMER Model
Diana Tamer, PharmD, BCOP; Timothy Schieber, PharmD, MBA; Jake Wodtke, PharmD; Samira Zantout, PharmD, BCPS
Read More
Review Article
Review Article, Biosimilars, Cost of Care
A Review of Clinical Data Among Biosimilars: Just How Similar Are They?
Dennis Marjoncu, PharmD, BCOP
Read More
FDA Updates
FDA Updates
FDA Accelerated the Approval of Columvi for Selected Relapsed or Refractory Large B-Cell Lymphomas
Read More
FDA Updates
Lonsurf Received a New Indication, in Combination With Bevacizumab, for Previously Treated Metastatic Colorectal Cancer
Read More
FDA Updates
Jemperli Plus Chemotherapy Now FDA Approved for Front-Line Treatment of dMMR or MSI-H Endometrial Cancer
Read More
FDA Updates
Vanflyta Now Approved for Newly Diagnosed FLT3-ITD–Positive AML
Read More
FDA Updates
Talzenna Received a New Indication, With Enzalutamide, for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Mutation
Read More